Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03349333 · OUTCOME

Overall Survival (OS)

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL · Source last updated 2019-10-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
4 years

What was measured

OS was measured from treatment day 1 until death or censoring.

Analysis population: The secondary analyses was performed using the safety population and repeated using the per-protocol population.

Groups in this outcome

Pralatrexate

Vitamin B12 and folic acid will be taken concurrently with pralatrexate pralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle. Vitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pralatrexate71

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pralatrexate18.00Not reported10.35NAThis analysis is based on cut off data, there are no enough events to estimated upper limit of 95% CI of median OS.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        This analysis is based on cut off data, there are no enough events to estimated upper limit of 95% CI of median OS.
        group Id
        OG000
        lower Limit
        10.35
        upper Limit
        NA
        value
        18.00
denoms
  1. counts
    1. group Id
      OG000
      value
      71
    units
    Participants
description
OS was measured from treatment day 1 until death or censoring.
dispersion Type
95% Confidence Interval
groups
  1. description
    Vitamin B12 and folic acid will be taken concurrently with pralatrexate pralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle. Vitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
    id
    OG000
    title
    Pralatrexate
param Type
MEDIAN
population Description
The secondary analyses was performed using the safety population and repeated using the per-protocol population.
reporting Status
POSTED
time Frame
4 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice